烟酰胺核糖对非酒精性脂肪肝病影响的研究进展
Research Progress on the Effects of Nicotinamide Riboside on Non-Alcoholic Fatty Liver Disease
摘要: 非酒精性脂肪肝病(nonalcoholic fatty liver disease, NAFLD)已成为全球最常见的慢性肝病，其患病率逐年升高。大多数NAFLD患者只患有简单的脂肪变性，肝脏中脂质积累，但其中一部分人会发展为非酒精性脂肪性肝炎(nonalcoholic steatohepatitis, NASH)，其特征是纤维化、炎症和肝细胞死亡。如果放任不管，NASH可能会发展为肝硬化和肝细胞癌，甚至导致死亡。NAFLD患病率的上升导致了严重的社会和经济问题。烟酰胺核糖(Nicotinamide Riboside, NR)是烟酰胺腺嘌呤二核苷酸(Nicotinamide Adenine Dinucleotide, NAD)的前体，在体内可以介导多种健康效应，补充NR可以减轻酒精引起的肝损伤，防止肝纤维化，并促进肝脏再生。本文对烟酰胺核糖用于治疗NAFLD的研究进行综述，旨在为烟酰胺核糖在临床治疗和保健品开发方面提供一定的科学依据。
Abstract: Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide, with its prevalence increasing year by year. Most NAFLD patients suffer from simple fatty degeneration, characterized by lipid accumulation in the liver. However, a portion of these patients may progress to non-alcoholic steatohepatitis (NASH), which is marked by fibrosis, inflammation, and hepatocyte death. If left untreated, NASH can lead to liver cirrhosis and hepatocellular carcinoma, and even result in mortality. The rising prevalence of NAFLD has led to significant social and economic issues. Nicotinamide riboside (NR) is a precursor to nicotinamide adenine dinucleotide (NAD) and can mediate various health effects within the body. Supplementing NR can alleviate alcohol-induced liver injury, prevent liver fibrosis, and promote liver regeneration. This article reviews the research on nicotinamide riboside in the treatment of NAFLD, aiming to provide scientific support for its clinical application and the development of health supplements.
文章引用：卞春勇. 烟酰胺核糖对非酒精性脂肪肝病影响的研究进展[J]. 临床医学进展, 2025, 15(1): 1139-1144. https://doi.org/10.12677/acm.2025.151151

参考文献

[1] Cohen, J.C., Horton, J.D. and Hobbs, H.H. (2011) Human Fatty Liver Disease: Old Questions and New Insights. Science, 332, 1519-1523. [Google Scholar] [CrossRef] [PubMed]
[2] Chen, F. and Liu, B. (2022) Sleeve Gastrectomy Suppresses Hepatic de Novo Cholesterogenesis and Improves Hepatic Cholesterol Accumulation in Obese Rats with Type 2 Diabetes Mellitus. Nutrition, 94, Article 111531. [Google Scholar] [CrossRef] [PubMed]
[3] Byrne, C.D. and Targher, G. (2015) NAFLD: A Multisystem Disease. Journal of Hepatology, 62, S47-S64. [Google Scholar] [CrossRef] [PubMed]
[4] Allen, A.M., Lazarus, J.V. and Younossi, Z.M. (2023) Healthcare and Socioeconomic Costs of NAFLD: A Global Framework to Navigate the Uncertainties. Journal of Hepatology, 79, 209-217. [Google Scholar] [CrossRef] [PubMed]
[5] Eslam, M., Newsome, P.N., Sarin, S.K., Anstee, Q.M., Targher, G., Romero-Gomez, M., et al. (2020) A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement. Journal of Hepatology, 73, 202-209. [Google Scholar] [CrossRef] [PubMed]
[6] Alegre, G.F.S. and Pastore, G.M. (2023) NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health. Current Nutrition Reports, 12, 445-464. [Google Scholar] [CrossRef] [PubMed]
[7] Bieganowski, P. and Brenner, C. (2004) Discoveries of Nicotinamide Riboside as a Nutrient and Conserved NRK Genes Establish a Preiss-Handler Independent Route to NAD+ in Fungi and Humans. Cell, 117, 495-502. [Google Scholar] [CrossRef] [PubMed]
[8] Haigis, M.C. and Sinclair, D.A. (2010) Mammalian Sirtuins: Biological Insights and Disease Relevance. Annual Review of Pathology: Mechanisms of Disease, 5, 253-295. [Google Scholar] [CrossRef] [PubMed]
[9] Imai, S. and Yoshino, J. (2013) The Importance of NAMPT/NAD/SIRT1 in the Systemic Regulation of Metabolism and Ageing. Diabetes, Obesity and Metabolism, 15, 26-33. [Google Scholar] [CrossRef] [PubMed]
[10] Verdin, E. (2014) The Many Faces of Sirtuins: Coupling of NAD Metabolism, Sirtuins and Lifespan. Nature Medicine, 20, 25-27. [Google Scholar] [CrossRef] [PubMed]
[11] Conze, D., Crespo-Barreto, J. and Kruger, C. (2016) Safety Assessment of Nicotinamide Riboside, a Form of Vitamin B3. Human & Experimental Toxicology, 35, 1149-1160. [Google Scholar] [CrossRef] [PubMed]
[12] Zhao, H., Tian, Y., Zuo, Y., Zhang, X., Gao, Y., Wang, P., et al. (2022) Nicotinamide Riboside Ameliorates High-Fructose-Induced Lipid Metabolism Disorder in Mice via Improving FGF21 Resistance in the Liver and White Adipose Tissue. Food & Function, 13, 12400-12411. [Google Scholar] [CrossRef] [PubMed]
[13] Serrano, A., Palou, A., Bonet, M.L. and Ribot, J. (2022) Nicotinamide Riboside Supplementation to Suckling Male Mice Improves Lipid and Energy Metabolism in Skeletal Muscle and Liver in Adulthood. Nutrients, 14, Article 2259. [Google Scholar] [CrossRef] [PubMed]
[14] Chen, G., Su, H., Lin, Y., Tsou, P., Chyuan, J. and Chao, P. (2016) A Conjugated Fatty Acid Present at High Levels in Bitter Melon Seed Favorably Affects Lipid Metabolism in Hepatocytes by Increasing NAD+/NADH Ratio and Activating PPARα, AMPK and SIRT1 Signaling Pathway. The Journal of Nutritional Biochemistry, 33, 28-35. [Google Scholar] [CrossRef] [PubMed]
[15] Shi, H., Xu, C., Liu, M., Wang, B., Liu, W., Chen, D., et al. (2018) Resveratrol Improves the Energy Sensing and Glycolipid Metabolism of Blunt Snout Bream Megalobrama amblycephala Fed High-Carbohydrate Diets by Activating the AMPK-SIRT1-PGC-1α Network. Frontiers in Physiology, 9, Article 1258. [Google Scholar] [CrossRef] [PubMed]
[16] de Gregorio, E., Colell, A., Morales, A. and Marí, M. (2020) Relevance of SIRT1-NF-κB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease. International Journal of Molecular Sciences, 21, Article 3858. [Google Scholar] [CrossRef] [PubMed]
[17] Yeung, F., Hoberg, J.E., Ramsey, C.S., Keller, M.D., Jones, D.R., Frye, R.A., et al. (2004) Modulation of NF-κB-Dependent Transcription and Cell Survival by the SIRT1 Deacetylase. The EMBO Journal, 23, 2369-2380. [Google Scholar] [CrossRef] [PubMed]
[18] Pham, T.X., Bae, M., Kim, M., Lee, Y., Hu, S., Kang, H., et al. (2019) Nicotinamide Riboside, an NAD+ Precursor, Attenuates the Development of Liver Fibrosis in a Diet-Induced Mouse Model of Liver Fibrosis. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1865, 2451-2463. [Google Scholar] [CrossRef] [PubMed]
[19] Pellicoro, A., Ramachandran, P. and Iredale, J.P. (2012) Reversibility of Liver Fibrosis. Fibrogenesis & Tissue Repair, 5, Article No. S26. [Google Scholar] [CrossRef] [PubMed]
[20] Troeger, J.S., Mederacke, I., Gwak, G., Dapito, D.H., Mu, X., Hsu, C.C., et al. (2012) Deactivation of Hepatic Stellate Cells during Liver Fibrosis Resolution in Mice. Gastroenterology, 143, 1073-1083.e22. [Google Scholar] [CrossRef] [PubMed]
[21] Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., et al. (2012) Myofibroblasts Revert to an Inactive Phenotype during Regression of Liver Fibrosis. Proceedings of the National Academy of Sciences, 109, 9448-9453. [Google Scholar] [CrossRef] [PubMed]
[22] Friedman, S.L. (2008) Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver. Physiological Reviews, 88, 125-172. [Google Scholar] [CrossRef] [PubMed]
[23] Bae, M., Park, Y. and Lee, J. (2018) Food Components with Antifibrotic Activity and Implications in Prevention of Liver Disease. The Journal of Nutritional Biochemistry, 55, 1-11. [Google Scholar] [CrossRef] [PubMed]
[24] Zhang, J. and Chen, F. (2024) Integrated Transcriptome and Metabolome Study Reveal the Therapeutic Effects of Nicotinamide Riboside and Nicotinamide Mononucleotide on Nonalcoholic Fatty Liver Disease. Biomedicine & Pharmacotherapy, 175, Article 116701. [Google Scholar] [CrossRef] [PubMed]
[25] Chiarugi, A., Dölle, C., Felici, R. and Ziegler, M. (2012) The NAD Metabolome—A Key Determinant of Cancer Cell Biology. Nature Reviews Cancer, 12, 741-752. [Google Scholar] [CrossRef] [PubMed]
[26] Wu, L.E., Gomes, A.P. and Sinclair, D.A. (2014) Geroncogenesis: Metabolic Changes during Aging as a Driver of Tumorigenesis. Cancer Cell, 25, 12-19. [Google Scholar] [CrossRef] [PubMed]
[27] Tummala, K.S., Gomes, A.L., Yilmaz, M., Graña, O., Bakiri, L., Ruppen, I., et al. (2014) Inhibition of de Novo NAD+ Synthesis by Oncogenic URI Causes Liver Tumorigenesis through DNA Damage. Cancer Cell, 26, 826-839. [Google Scholar] [CrossRef] [PubMed]
[28] Santidrian, A.F., Matsuno-Yagi, A., Ritland, M., Seo, B.B., LeBoeuf, S.E., Gay, L.J., et al. (2013) Mitochondrial Complex I Activity and NAD+/NADH Balance Regulate Breast Cancer Progression. Journal of Clinical Investigation, 123, 1068-1081. [Google Scholar] [CrossRef] [PubMed]
[29] Pang, N., Hu, Q., Zhou, Y., Xiao, Y., Li, W., Ding, Y., et al. (2023) Nicotinamide Adenine Dinucleotide Precursor Suppresses Hepatocellular Cancer Progression in Mice. Nutrients, 15, Article 1447. [Google Scholar] [CrossRef] [PubMed]
[30] Li, X., Yang, H., Jin, H., Turkez, H., Ozturk, G., Doganay, H.L., et al. (2023) The Acute Effect of Different NAD+ Precursors Included in the Combined Metabolic Activators. Free Radical Biology and Medicine, 205, 77-89. [Google Scholar] [CrossRef] [PubMed]

为你推荐